Citation Impact
Citing Papers
Phase I Dose-Escalation Study of Taselisib, an Oral PI3K Inhibitor, in Patients with Advanced Solid Tumors
2017
Kinome-Wide RNA Interference Screen Reveals a Role for PDK1 in Acquired Resistance to CDK4/6 Inhibition in ER-Positive Breast Cancer
2017
A First-in-Human, Phase I, Dose-Escalation Study of TAK-117, a Selective PI3Kα Isoform Inhibitor, in Patients with Advanced Solid Malignancies
2017
Evidence for Efficacy of New Hsp90 Inhibitors Revealed by Ex Vivo Culture of Human Prostate Tumors
2012
BAY 80-6946 Is a Highly Selective Intravenous PI3K Inhibitor with Potent p110α and p110δ Activities in Tumor Cell Lines and Xenograft Models
2013
Ganetespib, a Unique Triazolone-Containing Hsp90 Inhibitor, Exhibits Potent Antitumor Activity and a Superior Safety Profile for Cancer Therapy
2011
Combination Therapy of Bortezomib with Novel Targeted Agents: An Emerging Treatment Strategy
2010
Alpelisib for PIK3CA -Mutated, Hormone Receptor–Positive Advanced Breast Cancer
2019 Standout
Ganetespib (STA-9090), a Nongeldanamycin HSP90 Inhibitor, Has Potent Antitumor Activity in In Vitro and In Vivo Models of Non–Small Cell Lung Cancer
2012
Systematic Functional Characterization of Resistance to PI3K Inhibition in Breast Cancer
2016
First-in-Human Phase I Dose Escalation Study of a Second-Generation Non-Ansamycin HSP90 Inhibitor, AT13387, in Patients with Advanced Solid Tumors
2014
Intermittent High-Dose Scheduling of AZD8835, a Novel Selective Inhibitor of PI3Kα and PI3Kδ, Demonstrates Treatment Strategies for PIK3CA -Dependent Breast Cancers
2016
A Multicenter Phase I Trial of PX-866, an Oral Irreversible Phosphatidylinositol 3-Kinase Inhibitor, in Patients with Advanced Solid Tumors
2012
Bispecific antibodies for cancer therapy
2009
Fulvestrant plus palbociclib versus fulvestrant plus placebo for treatment of hormone-receptor-positive, HER2-negative metastatic breast cancer that progressed on previous endocrine therapy (PALOMA-3): final analysis of the multicentre, double-blind, phase 3 randomised controlled trial
2016 Standout
Plasma Hsp90 levels in patients with systemic sclerosis and relation to lung and skin involvement: a cross-sectional and longitudinal study
2021 Standout
Measurement of PIP3 Levels Reveals an Unexpected Role for p110β in Early Adaptive Responses to p110α-Specific Inhibitors in Luminal Breast Cancer
2014
Breast cancer
2019 Standout
Modular Strategy for the Construction of Radiometalated Antibodies for Positron Emission Tomography Based on Inverse Electron Demand Diels–Alder Click Chemistry
2011
Platelet factor 4–induced T H 1-T reg polarization suppresses antitumor immunity
2024 StandoutScienceNobel
Targeted inhibition of Hsp90 by ganetespib is effective across a broad spectrum of breast cancer subtypes
2013
Lapatinib and 17AAG Reduce 89Zr-Trastuzumab-F(ab′)2 Uptake in SKBR3 Tumor Xenografts
2012
Combination of Antibody That Inhibits Ligand-Independent HER3 Dimerization and a p110α Inhibitor Potently Blocks PI3K Signaling and Growth of HER2+ Breast Cancers
2013
PIK3CA mutations in breast cancer: reconciling findings from preclinical and clinical data
2014
Chimeric Antigen Receptor–Modified T Cells for Acute Lymphoid Leukemia
2013 Standout
Targeting cancer stem cell pathways for cancer therapy
2020
A view on drug resistance in cancer
2019 StandoutNature
Targeted Therapy for Breast Cancer
2013
PET imaging with 89Zr: From radiochemistry to the clinic
2012
Drug discovery approaches targeting the PI3K/Akt pathway in cancer
2008
Metformin-like antidiabetic, cardio-protective and non-glycemic effects of naringenin: Molecular and pharmacological insights
2017
Ovarian cancer
2014 Standout
Strictly Target Cell-dependent Activation of T Cells by Bispecific Single-chain Antibody Constructs of the BiTE Class
2007
Local secretion of anti-CTLA-4 enhances the therapeutic efficacy of a cancer immunotherapy with reduced evidence of systemic autoimmunity
2008 StandoutNobel
Resistance to Therapy
2016
Cisplatin Resistance: A Cellular Self-Defense Mechanism Resulting from Multiple Epigenetic and Genetic Changes
2012
Hallmarks of aging: An expanding universe
2023 Standout
Macrophages in immunoregulation and therapeutics
2023 Standout
Influence of tumour micro-environment heterogeneity on therapeutic response
2013 StandoutNature
Advances in the treatment of advanced oestrogen-receptor-positive breast cancer
2016
Hsp90 inhibition as a means to inhibit activation of the NLRP3 inflammasome
2018
Tumour-specific PI3K inhibition via nanoparticle-targeted delivery in head and neck squamous cell carcinoma
2017
CD19-/CD3-bispecific antibody of the BiTE class is far superior to tandem diabody with respect to redirected tumor cell lysis
2006
The complexity of NF-κB signaling in inflammation and cancer
2013 Standout
Targeting the phosphoinositide 3-kinase pathway in cancer
2009 Standout
Delivery technologies for cancer immunotherapy
2019 Standout
Feedback Suppression of PI3Kα Signaling in PTEN-Mutated Tumors Is Relieved by Selective Inhibition of PI3Kβ
2014
Hypoxia and the extracellular matrix: drivers of tumour metastasis
2014 StandoutNobel
Inflammation and tumor progression: signaling pathways and targeted intervention
2021 Standout
The generation, activation, and polarization of monocyte-derived macrophages in human malignancies
2023
Potent antibody therapeutics by design
2006
Elimination of large tumors in mice by mRNA-encoded bispecific antibodies
2017 StandoutNobel
The JAK/STAT signaling pathway: from bench to clinic
2021 Standout
Targeting apoptosis in cancer therapy
2020 Standout
Drug repurposing: progress, challenges and recommendations
2018 Standout
The RAS/RAF/MEK/ERK and the PI3K/AKT signalling pathways: role in cancer pathogenesis and implications for therapeutic approaches
2012
Emerging Role of mTOR in the Response to Cancer Therapeutics
2016
A practical guide to the construction of radiometallated bioconjugates for positron emission tomography
2011
The evolving tumor microenvironment: From cancer initiation to metastatic outgrowth
2023 Standout
Matching chelators to radiometals for radiopharmaceuticals
2013 Standout
Modulation of EZH2 expression in T cells improves efficacy of anti–CTLA-4 therapy
2018 StandoutNobel
Strategies and challenges for the next generation of antibody–drug conjugates
2017 Standout
PI3K in cancer: divergent roles of isoforms, modes of activation and therapeutic targeting
2014
Ganetespib blocks HIF-1 activity and inhibits tumor growth, vascularization, stem cell maintenance, invasion, and metastasis in orthotopic mouse models of triple-negative breast cancer
2013 StandoutNobel
Targeting the biology of ageing with mTOR inhibitors to improve immune function in older adults: phase 2b and phase 3 randomised trials
2021
Cisplatin in cancer therapy: Molecular mechanisms of action
2014 Standout
Bispecific antibodies for cancer therapy: A review
2017
AKT/PKB Signaling: Navigating the Network
2017 Standout
Macrophage M1/M2 polarization
2020 Standout
Development of PI3K/AKT/mTOR Pathway Inhibitors and Their Application in Personalized Therapy for Non–Small-Cell Lung Cancer
2012
Inhibition of PI3K/Akt/mTOR pathway by apigenin induces apoptosis and autophagy in hepatocellular carcinoma cells
2018 Standout
The PI3K Pathway in Human Disease
2017 Standout
Targeting PI3K signalling in cancer: opportunities, challenges and limitations
2009 Standout
Renal cell carcinoma
2017 Standout
Clinical relevance of tumour-associated macrophages
2022
PDK1-SGK1 Signaling Sustains AKT-Independent mTORC1 Activation and Confers Resistance to PI3Kα Inhibition
2016
Chimeric antigen receptor T-cell therapy — assessment and management of toxicities
2017 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
A phase 1 study of the sachet formulation of the oral dual PI3K/mTOR inhibitor BEZ235 given twice daily (BID) in patients with advanced solid tumors
2015
Emerging targeted agents in metastatic breast cancer
2013
Macrophages as tools and targets in cancer therapy
2022
Cu and Cu-Based Nanoparticles: Synthesis and Applications in Catalysis
2016 Standout
Imaging the distribution of an antibody-drug conjugate constituent targeting mesothelin with 89Zr and IRDye 800CW in mice bearing human pancreatic tumor xenografts
2015
The MAPK pathway across different malignancies: A new perspective
2014 Standout
The NLRP3 Inflammasome: An Overview of Mechanisms of Activation and Regulation
2019 Standout
89Zr-Radiolabeled Trastuzumab Imaging in Orthotopic and Metastatic Breast Tumors
2012
Akt Signaling in Macrophage Polarization, Survival, and Atherosclerosis
2019
Picking the Point of Inhibition: A Comparative Review of PI3K/AKT/mTOR Pathway Inhibitors
2014 Standout
Regulation of Apoptosis by HER2 in Breast Cancer
2013
Molecular docking studies on the interaction of NCI anticancer analogues with human Phosphatidylinositol 4,5-bisphosphate 3-kinase catalytic subunit
2019
Chromone: A Valid Scaffold in Medicinal Chemistry
2014 Standout
Iterative in Situ Click Chemistry Assembles a Branched Capture Agent and Allosteric Inhibitor for Akt1
2011 StandoutNobel
A Phase Ib Study of Alpelisib (BYL719), a PI3Kα-Specific Inhibitor, with Letrozole in ER+/HER2− Metastatic Breast Cancer
2016
An investigation into the identification of potential inhibitors of SARS-CoV-2 main protease using molecular docking study
2020 Standout
Synthesis of Heterobifunctional Protein Fusions Using Copper‐Free Click Chemistry and the Aldehyde Tag
2012 StandoutNobel
The Hsp90 inhibitor NVP-AUY922-AG inhibits NF-κB signaling, overcomes microenvironmental cytoprotection and is highly synergistic with fludarabine in primary CLL cells
2012
Proteasome Inhibition Alleviates SNARE-Dependent Neurodegeneration
2012 StandoutNobel
A Phase Ib Study of BEZ235, a Dual Inhibitor of Phosphatidylinositol 3-Kinase (PI3K) and Mammalian Target of Rapamycin (mTOR), in Patients With Advanced Renal Cell Carcinoma
2016
Tumor Regression in Cancer Patients by Very Low Doses of a T Cell–Engaging Antibody
2008 Science
Plasma Levels of Heat Shock Protein 90 Alpha Associated with Lung Cancer Development and Treatment Responses
2014
The STRING database in 2021: customizable protein–protein networks, and functional characterization of user-uploaded gene/measurement sets
2020 Standout
PI3K pathway regulates ER-dependent transcription in breast cancer through the epigenetic regulator KMT2D
2017 Science
Nanobodies: Natural Single-Domain Antibodies
2013 Standout
Important Flavonoids and Their Role as a Therapeutic Agent
2020 Standout
Works of Cornelia Quadt being referenced
The HSP90 Inhibitor NVP-AUY922 Potently Inhibits Non–Small Cell Lung Cancer Growth
2013
First-in-Human Phase I Dose-Escalation Study of the HSP90 Inhibitor AUY922 in Patients with Advanced Solid Tumors
2013
Inhibition of HSP90 with AUY922 Induces Synergy in HER2-Amplified Trastuzumab-Resistant Breast and Gastric Cancer
2013
Phosphatidylinositol 3-Kinase α–Selective Inhibition With Alpelisib (BYL719) in PIK3CA-Altered Solid Tumors: Results From the First-in-Human Study
2018
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
2012
NVP-AUY922: a small molecule HSP90 inhibitor with potent antitumor activity in preclinical breast cancer models
2008
Phase 1/1b dose escalation and expansion study of BEZ235, a dual PI3K/mTOR inhibitor, in patients with advanced solid tumors including patients with advanced breast cancer
2018
Signalling profile and antitumour activity of the novel Hsp90 inhibitor NVP-AUY922 in multiple myeloma
2008
89Zr-Bevacizumab PET of Early Antiangiogenic Tumor Response to Treatment with HSP90 Inhibitor NVP-AUY922
2010
PI3K inhibitors as new cancer therapeutics: implications for clinical trial design
2016
89Zr-trastuzumab PET visualises HER2 downregulation by the HSP90 inhibitor NVP-AUY922 in a human tumour xenograft
2009
T-cell activation and B-cell depletion in chimpanzees treated with a bispecific anti-CD19/anti-CD3 single-chain antibody construct
2005
A phase I study with adecatumumab, a human antibody directed against epithelial cell adhesion molecule, in hormone refractory prostate cancer patients
2006
Activity of New Heat Shock Protein 90 (hsp90) Inhibitor NVP-AUY922 Against Myeloma Cells Sensitive and Resistant to Conventional Agents.
2007
Abstract PD5-5: Phase I study of the PI3Kα inhibitor BYL719 plus fulvestrant in patients with PIK3CA-altered and wild type ER+/HER2- locally advanced or metastatic breast cancer
2015
Abstract P2-16-14: Preliminary safety, pharmacokinetics and anti-tumor activity of BYL719, an alpha-specific PI3K inhibitor in combination with fulvestrant: Results from a phase I study
2013
AUY922, a novel HSP90 inhibitor: Final results of a first-in-human study in patients with advanced solid malignancies.
2010
A phase I/IB dose-escalation study of BEZ235 in combination with trastuzumab in patients with PI3-kinase or PTEN altered HER2+ metastatic breast cancer.
2012
Oral PI3 kinase inhibitor BKM120 monotherapy in patients (pts) with advanced solid tumors: An update on safety and efficacy.
2011
A dose-escalation study with the novel formulation of the oral pan-class I PI3K inhibitor BEZ235, solid dispersion system (SDS) sachet, in patients with advanced solid tumors.
2011
Abstract CT171: Phase I study of BLZ945 alone and with spartalizumab (PDR001) in patients (pts) with advanced solid tumors
2020
Abstract 3749: Single agent activity of PIK3CA inhibitor BYL719 in a broad cancer cell line panel
2012
Phase I dose‐escalation study of buparlisib (BKM 120), an oral pan‐class I PI 3K inhibitor, in Japanese patients with advanced solid tumors
2014
Abstract CT-01: BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
2012
Abstract P6-10-07: Phase I study of BYL719, an alpha-specific PI3K inhibitor, in patients with PIK3CA mutant advanced solid tumors: preliminary efficacy and safety in patients with PIK3CA mutant ER-positive (ER+) metastatic breast cancer (MBC)
2012
Safety, pharmacokinetics, and preliminary activity of the α-specific PI3K inhibitor BYL719: Results from the first-in-human study.
2013